جميع الدراسات
التوظيفالتأكيد العلاجي (المرحلة الثالثة)تداخلي

A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type

This important study is looking into a new medication called AVP-786. It's designed for people living with Alzheimer's disease who sometimes become agitated. Researchers want to find out if this medicine can help make these feelings of agitation less severe. They also want to understand if the medicine is safe and if people can take it without too many side effects. To do this, some participants will receive the actual medicine, while others will receive a placebo – a pill that looks the same but contains no active medicine. This allows researchers to compare the effects accurately. The study will measure changes in agitation over time to see how well the treatment works.

نظرة سريعة

الحالة
التوظيف
المرحلة
التأكيد العلاجي (المرحلة الثالثة)
الراعي
Otsuka Pharmaceutical Development & Commercialization Inc., Otsuka Pharmaceutical Development & Commercialization Inc.
الهدف من التسجيل
267
ابدأ
14 May 2024

ما هو موضوع هذه الدراسة؟

This study is about helping people with Alzheimer's disease who experience agitation. Agitation can mean someone feels restless, anxious, or distressed, and it can be challenging for both the person with dementia and their carers. Researchers are testing a new medicine called AVP-786 to see if it can help reduce these feelings.

Imagine a large group of people with Alzheimer's who experience agitation. Half of them will receive the new medicine, AVP-786, and the other half will receive a 'dummy' pill, called a placebo. Neither the patients nor their doctors will know who is getting which. This is done so everyone can be sure that any changes seen are truly due to the medicine and not just other factors.

The main goal is to measure how much agitation changes in people taking the medicine compared to those taking the dummy pill. They will use special ways to score agitation levels at the beginning and again at the end of the study. They also want to see if the medicine is safe and doesn't cause too many unwanted side effects. The results from this study will help doctors decide if AVP-786 could be a helpful treatment option in the future.

النقاط الرئيسية

  • This study is testing a new medicine for agitation in Alzheimer's.
  • It aims to see if AVP-786 is safe and effective.
  • Participants will get either the new medicine or a dummy pill.
  • The study helps advance understanding of Alzheimer's treatments.
  • Your participation is voluntary and you can withdraw at any time.

من قد يكون مؤهلاً؟

This study is looking for both men and women aged 18 or older. Participants must have been diagnosed with Alzheimer's disease and be experiencing agitation.

There might be other specific health requirements or medications that could prevent someone from joining. These details would be discussed with you by the study doctor to make sure the study is a good fit.

It's very important that you or your loved one meet all the study's requirements to ensure everyone's safety and to make sure the study results are reliable.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 18 سنة أو أكثر؟
  2. Do you have a diagnosis of Alzheimer's disease?
  3. Are you currently experiencing agitation?
  4. Are you able to attend regular study visits?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part, you would receive either the new study medication, AVP-786, or a placebo (a dummy pill). The study involves regular visits to the clinic where doctors and nurses will check your health, ask questions about your agitation levels, and monitor any side effects. You'll likely have physical exams and potentially some blood tests. The medication would need to be taken as directed. The study would last for a specific period, and after you stop taking the study medication, there might be follow-up visits to ensure your well-being. The total length of your involvement will be clearly explained by the study team.

المخاطر والفوائد المحتملة

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is that the new medicine might help reduce agitation. You would also be contributing to medical research that could help many others in the future. However, there's no guarantee the medicine will work, and you might experience side effects, just like with any medication. You are free to leave the study at any time, for any reason, without it affecting your medical care.

المواقع (7)

بعض مواقع الأماكن تقريبية. نحن نعمل على تحسين ذلك — يرجى التحقق مع فريق التجربة قبل السفر.
  • —
    غير مؤكد
    اليونان
  • —
    غير مؤكد
    إستونيا
  • —
    غير مؤكد
    بلغاريا
  • —
    غير مؤكد
    بولندا
  • —
    غير مؤكد
    البرتغال
  • —
    غير مؤكد
    الدنمارك
  • —
    غير مؤكد
    ألمانيا

أسئلة شائعة

What is agitation?

Agitation in Alzheimer's disease can mean feeling restless, anxious, irritable, or distressed. It's often expressed through actions like pacing, fiddling, or shouting.

ما هو الدواء الوهمي؟

A placebo is a 'dummy' pill or treatment that looks exactly like the real medicine but doesn't contain any active drug. It helps researchers compare the effects of the new medicine accurately.

What is AVP-786?

AVP-786 is the name of the new medicine being tested in this study. It's a combination of two ingredients: deudextromethorphan hydrobromide and quinidine sulfate, which work together.

هل سأعرف إذا كنت أحصل على الدواء أم الدواء الوهمي؟

No, neither you nor your study doctor will know whether you are receiving the real medicine or the placebo. This is called 'double-blind' and is a standard way to get fair results.

كم ستستغرق مدة الدراسة؟

The total length of the study for an individual will be explained by the research team. It usually involves a period of taking the medication and some follow-up visits.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Phase 3, multicenter, randomized, double-blind, placebo-co… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.